Immunogenicity and Safety Study of NBP615 in Healthy Female

\[Inclusion Criteria\] * Healthy adult(19 to 26 years)/adolescent(9 to 13 years) of age at the time of the 1st vaccination * Participant fully understands study procedures, and voluntarily agrees to participate in the study and follow the study procedure by giving written informed consent \[Exclusion Criteria\] * Received a marketed Human papillomavirus(HPV) vaccine, or had participated in an HPV vaccine clinical trial and had received either active agent or placebo. * History of hypersensitivity to any component of the study vaccines. * Currently immunocompromised or was diagnosed as having a congenital or acquired immunodeficiency, Human Immunodeficiency Virus(HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, other autoimmune condition, or other immune disorder which is decided to be medically significant by the investigator. * Received immunoglobulins and/or blood product within 3 months preceding the first dose of study vaccine or planned administration during the study period. * Receiving or had received chemotherapy, immunosuppressive therapies, or radiation therapy in the year prior to enrolment. * Chronic administration (\>14 days) of immune-suppressants or immune modulating drugs within 3 months prior to the first vaccine dose or planned administration during the study period. Inhaled, nasal and topical steroids are allowed. * Participant with severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections. * Subject has active cervical disease or a significant history of cervical disease.